Bill Ackman Archives - CFO

Bill Ackman’s SPAC Hit With Lawsuit

Risk & Compliance

Bill Ackman’s SPAC Hit With Lawsuit

The case contends that Ackman’s Pershing Square Capital Management is actually an investment company and should be regulated as such.

By Matthew Heller | August 18, 2021

Bill Ackman Files for Largest-Ever SPAC Offering

Bill Ackman Files for Largest-Ever SPAC Offering

The investor is betting that blank-check mergers continue to be an attractive alternative to traditional IPOs amid the current market volatility.

By Matthew Heller | June 24, 2020

ADP Needs a New CFO, Says Research Firm

ADP Needs a New CFO, Says Research Firm

In rebutting Bill Ackman's call for a new CEO of ADP, Management CV suggests the problem is in the finance chief's office.

By Vincent Ryan | September 18, 2017

Ackman Presses for Strategy Changes at ADP

Ackman Presses for Strategy Changes at ADP

The activist investor says ADP could more than double its stock price if it cut staff and made better investments in technology.

By Matthew Heller | August 17, 2017

Bill Ackman, ADP Heading for Proxy Fight?

Risk & Compliance

Bill Ackman, ADP Heading for Proxy Fight?

The activist investor is planning to name a minority slate to the ADP board as he seeks "transformational change" at the company.

By Matthew Heller | August 4, 2017

Herbalife to Revamp Distributor Compensation

Risk & Compliance

Herbalife to Revamp Distributor Compensation

The company will restructure its compensation system to settle FTC charges that it made false promises to distributors about their potential income.

By Matthew Heller | July 15, 2016

Regulator Bars Valeant Officers From Trading

Risk & Compliance

Regulator Bars Valeant Officers From Trading

A Canadian regulator issues a cease trade order after the troubled drug maker announces it would be late filing financial reports.

By Katie Kuehner-Hebert | April 1, 2016

Railways: Doing the Locomotion

Railways: Doing the Locomotion

The second golden age of American railroads is drawing to a close. Consolidation may follow.

By Economist Staff | February 16, 2016

Roll-ups: Serial Thrillers

Roll-ups: Serial Thrillers

The agonies and ecstasies of firms that are addicted to doing takeovers.

By Economist Staff | December 21, 2015

Activist Investor Can’t Dodge Insider Trading Suit

Risk & Compliance

Activist Investor Can’t Dodge Insider Trading Suit

A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.

By Matthew Heller | November 12, 2015

Watchdogs Call for Shorter Window for Activist Disclosures

Watchdogs Call for Shorter Window for Activist Disclosures

Groups say loopholes in securities laws allow activist investors to secretly buy large stakes in companies before initiating hostile takeovers.

By Katie Kuehner-Hebert | April 17, 2015

Ackman’s Allergan Takeover Bid Is Easier Said Than Done

Ackman’s Allergan Takeover Bid Is Easier Said Than Done

The takeover contest's outcome becomes unclear when we consider the conflict between the hedge fund’s objectives and the Allergan board's fiduciary duty.

By Gardner Davis | June 16, 2014

Herbalife: The House of Cards Put

Herbalife: The House of Cards Put

Activist investing meets activist government.

By Economist Staff | March 14, 2014

Anything You Can Do, Icahn Do Better

Anything You Can Do, Icahn Do Better

The pressure on companies from activist shareholders continues to grow.

By Economist Staff | February 19, 2014